Sanofi Asthma Drug Lunsekimig Shows 55% Reduction in Exacerbations in Phase IIb Trial

Sanofi’s experimental asthma treatment lunsekimig has delivered encouraging Phase IIb results, including a 55.3% reduction in asthma exacerbations at its highest tested dose, strengthening the case for the drug to advance into Phase III development.

Detailed efficacy and safety findings from the Phase IIb AIRCULES study were presented at the 2026 European Respiratory Society (ERS) International Congress.

According to analysis from GlobalData, the results could make lunsekimig an increasingly important part of Sanofi’s respiratory pipeline as the pharmaceutical company prepares for the eventual loss of exclusivity of blockbuster drug Dupixent.

What Is Lunsekimig?

Lunsekimig is an investigational bispecific Nanobody, or VHH, designed to simultaneously target thymic stromal lymphopoietin (TSLP) and interleukin-13 (IL-13).

Both are involved in inflammatory pathways associated with asthma.

The treatment is being investigated as an add-on therapy for adults with moderate-to-severe asthma, with its dual-targeting mechanism potentially distinguishing it from existing biologic therapies that target individual inflammatory pathways.

Zaid Mahmood, Healthcare Analyst at GlobalData, said:

“The data presented at ERS 2026 confirmed dose-dependent efficacy alongside a clean safety profile, giving Sanofi a clear basis to advance lunsekimig into Phase III development.”

Exacerbations Fell Across All Three Dose Regimens

The AIRCULES trial evaluated three lunsekimig dosing regimens: 60mg every four weeks, 300mg every four weeks and 300mg every eight weeks.

Lunsekimig met the study’s primary endpoint across all three regimens, with the annualised asthma exacerbation rate (AAER) over 48 weeks falling progressively across the dose range.

However, only the highest-dose 300mg every-four-weeks regimen achieved statistical significance.

At that dose, the reduction in exacerbations reached 55.3%.

Mahmood said:

“A 55.3% reduction in exacerbations at the highest dose is a compelling outcome, and the consistent dose-response observed across all three regimens gives Sanofi a well-supported basis for selecting a lead dose for Phase III.”

Improvements were also observed in lung function.

Pre-bronchodilator forced expiratory volume in one second (FEV1), an important measure of how effectively a patient can expel air from their lungs, improved at week 48 across all treatment groups.

Again, the greatest improvement was reported among patients receiving the highest dose.

Safety Findings Support Further Development

Safety will be an important consideration as lunsekimig moves towards larger studies.

According to the Phase IIb findings, the treatment was generally well tolerated. Severe treatment-emergent adverse events were reported at levels comparable with or lower than placebo.

The combination of the reported dose-response relationship, improvement in lung function and safety profile provides Sanofi with data to support moving the programme into Phase III.

Larger Phase III trials will nevertheless be required to establish the treatment’s efficacy and safety more conclusively before any potential regulatory approval.

Lunsekimig Takes Greater Role in Sanofi’s Respiratory Pipeline

Beyond the clinical findings, lunsekimig could have considerable strategic importance for Sanofi.

Dupixent (dupilumab), developed by Sanofi and Regeneron, has become a major product across a range of inflammatory diseases, including asthma.

GlobalData said Dupixent generated more than $17 billion globally during 2025 across eight indications, while loss of exclusivity is expected in 2031.

Developing successful follow-on medicines is therefore becoming increasingly important to Sanofi as it looks towards the next generation of its immunology and respiratory portfolio.

Mahmood said:

“Following the discontinuation of itepekimab in COPD after mixed Phase III results, and the earlier discontinuation of amlitelimab in asthma, lunsekimig is now Sanofi’s leading respiratory pipeline asset.”

Competitive Asthma Biologics Market

Any eventual launch would put lunsekimig into an increasingly competitive market.

Six biologic treatments are already approved across five mechanisms of action, according to GlobalData.

Two particularly important comparisons are likely to be Dupixent itself, which has established a significant position in type 2-high asthma, and AstraZeneca and Amgen’s Tezspire (tezepelumab).

Tezspire targets TSLP and is notable for its use across a broad population of patients with severe asthma without requiring a particular biomarker threshold.

Lunsekimig’s bispecific mechanism could therefore become an important point of differentiation if later-stage clinical trials demonstrate meaningful benefits.

Mahmood concluded:

“The key opinion leaders interviewed by GlobalData are especially enthusiastic about the drug’s bispecific approach, especially if used in combination with other targeting biologics. Data from AIRCULES gives Sanofi a solid strategy to defend its position in the asthma market ahead of Dupixent’s patent expiry.”

The Phase IIb findings represent an important step rather than confirmation of lunsekimig’s eventual clinical success. Phase III studies will provide a more rigorous test of whether the improvements seen in AIRCULES can be replicated across larger patient populations.

If those results prove positive, however, lunsekimig could potentially give Sanofi another significant respiratory biologic as the pharmaceutical group prepares for a post-Dupixent-patent landscape.

—

Image: ChatGPT